Patent classifications
C12Y302/01052
CLEANING COMPOSITIONS INCLUDING NUCLEASE ENZYME AND MALODOR REDUCTION MATERIALS
Cleaning compositions that include a nuclease enzyme and one or more malodor reduction materials. Methods of making and using such cleaning compositions. Use of malodor reduction materials.
Detergent compositions and uses thereof
The present invention relates to polypeptides having hexosaminidase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Compositions for the Restoration of a Fecal Microbiota and Methods for Making and Using Them
In alternative embodiments, the invention provides compositions and methods for treating various disorders and conditions in mammals, including chronic disorders in which there is a presence of an abnormal microbiota or an abnormal distribution of microflora in the gastrointestinal tract. In alternative embodiments, the invention provides liquid preparations or formulations derived from a human fecal material (e.g., a stool) processed, e.g., filtered and/or centrifuged, such that all bacteria, fungal spores and viruses are removed, but retaining the native biologically active molecules from the fecal material and bacteriophages. In alternative embodiments, the invention provides a “rough-”, “incomplete-” or medium-filtered microbiota which still comprises native physiological components or nutritive agents for the bacteria, e.g., retains native biologically and nutritionally active components. In alternative embodiments, the invention provides a highly filtered or substantially purified microbiota in combination with, or having added back, a liquid preparation or formulation of the invention. In alternative embodiments, the invention provides compositions or formulations where the bacteria, or microbiota, component has been cultured, or cultured under anaerobic conditions, or harvested, stored and/or cultured under anaerobic conditions. In alternative embodiments, the invention provides various additives, compositions and donor restrictions for treating these disorders and conditions.
Modulation of AAV Vector Transgene Expression
Aspects of the invention relate to recombinant adeno-associated viruses (rAAVs). In some aspects, the rAAVs comprise artificial genetic regulatory elements that modulate transgene expression. In some aspects, the disclosure relates to the treatment of lysosomal storage disorders.
RAAV Vectors for the Treatment of GM1 and GM2 Gangliosidosis
Aspects of the disclosure relate to compositions and methods for the treatment of lysosomal storage disorders, such as GM1 gangliosidosis, Tay Sachs disease, and Sandhoff disease. In some embodiments, the compositions comprise viral vectors encoding beta-galactosidase. In some embodiments, the compositions comprise viral vectors encoding beta-hexosaminidase subunits (e.g. HEXA, HEXB, or combinations thereof).
CONDITIONING METHODS FOR GENE THERAPY
The disclosure provides compositions and methods useful for the depletion of a specific population of endogenous hematopoietic stem cells and/or immune cells from a subject prior to transplantation with genetically modified stem cells to improve the engraftment of the transplanted stem cells and provide gene therapy. The disclosure provides compositions and methods for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ or CD45+ cells in a patient, such as a human.
COMBINATION OF NASAL GENE DELIVERY AND ORAL CINNAMIC ACID, OLEAMIDE OR GEMFIBROZIL FOR LYSOSOMAL STOARGE DISORDERS
Provided herein are methods for the treatment of lysosomal storage disease comprising administration of genes encoding for a lysosomal enzyme and a pharmaceutical agent. Combining gene therapy with pharmaceutical compositions by co-administration not only further enhances the effects of each individual therapy, but also provides a multi-faceted approach to treatment because of the varying mechanism of action of each individual composition.
Detergent compositions and uses thereof
The present invention relates to polypeptides having hexosaminidase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
CLEANING COMPOSITIONS CONTAINING ALGINATE LYASE ENZYMES
Compositions including an alginate lyase enzyme and anionic surfactant. Methods of treating fabrics by contacting the fabric with an aqueous wash liquor having the detergent composition therein. The compositions and methods are particularly for improving whiteness of a fabric, improved soil removal from a fabric, for malodour removal from a fabric, for anti-wrinkle benefits, anti-redeposition benefits and/or for improved drying of a fabric.
CLEANING COMPOSITIONS AND USES THEREOF
The present disclosure relates to cleaning compositions and methods of deep cleaning surfaces and textiles. The cleaning compositions may include an enzyme having hexosaminidase activity and at least one perfume component.